ACB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aurora Cannabis Inc is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock just closed sharply lower, the technical trend is bearish, and there is no AI Stock Picker or SwingMax buy signal. While the company’s FY2026 results showed revenue growth and better profitability, guidance points to a revenue decline in FY27, which weakens the long-term case. My direct view: wait, do not buy now.
ACB is in a clear short-term bearish trend. Price closed at 3.07 after a 6.38% regular-session drop, with pre-market weakness as well. MACD histogram is negative and expanding, confirming downside momentum. Moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which typically signals an established downtrend. RSI_6 at 20.4 suggests the stock is oversold, but oversold alone is not a buy signal when trend and momentum remain negative. Key levels: support at 2.916 and 2.697; resistance at 3.622 and 3.841. Overall trend remains weak.
["FY2026 net revenue exceeded guidance by $8 million.", "Global medical cannabis net revenue rose 10% year-over-year, driven by Europe.", "Adjusted net income in Q4 was positive at C$5.6 million.", "Earnings beat expectations with EPS of 0.07 versus an estimate of -0.07."]
["Management expects FY27 revenue to decline due to headwinds in the Canadian medical cannabis unit.", "The stock sold off sharply after the latest results, showing weak near-term investor reaction.", "Technical trend is bearish across MACD and moving averages.", "No recent insider buying, no meaningful hedge fund buying trend, and no congress trading data."]
Aurora Cannabis reported FY2026 results on Q4 2026 pre-market. Revenue was strong at about C$320.6M to $321M, above guidance, and EPS came in at 0.07 versus an estimate of -0.07. Q4 adjusted net income was C$5.6M, indicating improved profitability. The company also reported global medical cannabis net revenue of CAD 84.8M, up 10% year-over-year, with Europe as a growth driver. The main concern is management’s expectation for FY27 revenue decline, which offsets the recent quarter's progress.
No analyst rating or price target change trend was provided in the data, so there is no clear Wall Street upgrade/downgrade momentum to rely on. Based on the available information, the pros view is that Aurora is showing improving profitability and revenue beats, but the cons view is that future growth is uncertain and the business still faces regional headwinds. Overall Wall Street-style sentiment from the supplied data appears mixed to cautious rather than strongly bullish.
